Bionova Capital is a healthcare-specialized venture capital firm based in Lisbon, Portugal.

From 2015 to 2024, Bionova Capital invested in early-stage life science startups across Europe, having secured two profitable exits, including one of the most successful biotech deals ever in Europe (CellmAbs).

In 2023, Bionova Capital’s team started an independent venture capital company named Biovance Capital Partners. Bionova’s team has fully transitioned to Biovance Capital Partners in 2024 upon the successful raise of Biovance Capital Fund I, a new fund up to € 60 million to invest in early-stage biotech companies across Europe.

Consequently, Bionova Capital has stopped making new investments and is only focused on the management of its current portfolio.